Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients.

CTLA, cytotoxic T-lymphocyte-associated antigen ECG, electrocardiogram ICI, immune checkpoint inhibitors IRAE, immunity-related adverse effects PD, programmed cell death receptor PDL, programmed cell death ligand cardiotoxicity immune checkpoint inhibitors immunity-related adverse events

Journal

JACC. Case reports
ISSN: 2666-0849
Titre abrégé: JACC Case Rep
Pays: Netherlands
ID NLM: 101757292

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 01 08 2019
revised: 13 11 2019
accepted: 18 11 2019
entrez: 28 7 2021
pubmed: 19 2 2020
medline: 19 2 2020
Statut: epublish

Résumé

We recount a single-center experience with cardiac immunity-related adverse effects in patients treated with immune checkpoint inhibitors. Of 2,830 patients, 9 patients (0.3%) developed cardiac immunity-related adverse effects (4 cases of cardiomyopathies, 2 of myocarditis, 2 of acute pericarditis, and 1 of large pericardial effusion). Disease profiles, hospital courses, and outcomes are reported. (

Identifiants

pubmed: 34317203
doi: 10.1016/j.jaccas.2019.11.080
pii: S2666-0849(19)30691-6
pmc: PMC8298653
doi:

Types de publication

Case Reports

Langues

eng

Pagination

191-199

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 The Authors.

Références

Circulation. 2007 Oct 30;116(18):2062-71
pubmed: 17938288
J Immunother Cancer. 2015 Apr 21;3:11
pubmed: 25901283
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Eur Heart J. 2015 Nov 7;36(42):2921-2964
pubmed: 26320112
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
Nat Med. 2003 Dec;9(12):1477-83
pubmed: 14595408
Br J Cancer. 2017 Sep 26;117(7):921-924
pubmed: 28797029
Ann Oncol. 2015 Dec;26(12):2375-91
pubmed: 26371282
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
N Engl J Med. 2019 Jun 13;380(24):2377-2379
pubmed: 31189043
J Immunother. 2018 Sep;41(7):332-335
pubmed: 29965858
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828
Science. 2001 Jan 12;291(5502):319-22
pubmed: 11209085
Lancet. 2018 Mar 10;391(10124):933
pubmed: 29536852
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
J Immunother Cancer. 2016 Aug 16;4:50
pubmed: 27532025
Circulation. 2019 Jul 02;140(2):80-91
pubmed: 31390169
Can J Cardiol. 2018 Jan;34(1):92.e1-92.e3
pubmed: 29275889
Lancet Oncol. 2018 Dec;19(12):1579-1589
pubmed: 30442497
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373

Auteurs

Johnny Chahine (J)

Department of Medicine, Cleveland Clinic Foundation, Cleveland, Ohio.

Patrick Collier (P)

Center for the Diagnosis and Treatment of Pericardial Diseases, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.

Anjli Maroo (A)

Department of Cardiovascular Medicine, Cleveland Clinic Foundation Fairview Hospital, Cleveland, Ohio.

W H Wilson Tang (WHW)

Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.

Allan L Klein (AL)

Center for the Diagnosis and Treatment of Pericardial Diseases, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.

Classifications MeSH